Acute Coronary Syndrome – Local / Regional Programs

AstraZeneca – Call For Grants (CGA CV 1601)
Local / Regional Programs
Therapeutic Area: Cardiovascular
Disease State: Acute Coronary Syndrome (ACS)
Call for Grants Application Title: “CGA CV 1601– Program Title…”
Your title must begin with Call for Grants Application (CGA) ID number.
Refer to Grant Submission Instructions for further information on submitting
your formal grant application.
Submission Timeframe:
1/5/2016 – 10/1/2016
Regional / local educational programs.
Multi-support encouraged
Local / regional live programs, enduring materials,
web-based programs, and institutional grand rounds
≤ $5,000.00
Program Format:
Program Cost:
AstraZeneca is interested in providing grant support for independent education
activities in the area of Acute Coronary Syndrome (ACS) that address increased
awareness and adherence to treatment guidelines, and provide evidence-based
solutions to meeting the unmet medical needs of patients.
Needs Assessment: For Acute Coronary Syndrome
According to The Year in Acute Coronary Syndrome (Giugliano & Braunwald,
2014), there were an estimated 1.1 million patients with a diagnosis of ACS upon
hospital discharge in the US alone in 2010. Despite improvements in the
management of coronary heart disease risk factors, the annual rates of myocardial
infarction have remained steady over the past ten years.
In 2014, new guidelines for the management of STEMI were published by the ACC /
AHA and the ESC. The UA and NSTEMI guidelines were also updated in several key
areas. Adherence to the guidelines for improved patient outcomes as well as quality
metrics / reimbursement, necessitate the need for further education for healthcare
Antiplatelet therapy remains one of the cornerstones for the management of ACS.
Several clinical trials have published outcomes on various therapies over the past
several years. Ongoing education is needed for HCPs as the guidelines change and
various therapies are utilized.
Adherence to secondary prevention medications following acute coronary syndrome
(ACS) is disappointingly low, standing around 40–75% by various estimates. This is
an inefficient use of the resources devoted to their development and implementation,
and also puts patients at higher risk of poor outcomes post-ACS. Numerous factors
contribute to low adherence including poor motivation, forgetfulness, lack of
education about medications, complicated polypharmacy of ACS regimens, (fear of)
adverse side effects and limited practical support.
Cheng, K., Ingram, N., Keenan, J., & Choudhury, R. Evidence of poor adherence to
secondary prevention after ACS: Possible remedies through the application of
new technologies. Open Heart 2015;2:doi-10.1136/openhrt-2014-000166.
Giugliano RP, Braunwald E. The Year in Acute Coronary Syndrome. J Am Coll
Cardiol 2014; 63:201-214
Libby P. Mechanisms of Acute coronary Syndromes and their Implications for
therapy. N Engl J Med 2013; 368:2004-13
O’Gara PT. Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA Guideline for the
Management of Acute Myocardial Infarction in Patients Presenting with STsegment elevation. Eur Heart J 2012; 33:2569-619.
Program Requirements:
The Program must be accredited and fully compliant with the criteria and/or
standards of commercial support for ACCME, AAFP, AOA, ACPE, ANCC, AANP, or
NCCPA. Furthermore, the program will be educational and non-promotional in
nature and will be planned, designed and implemented in accordance with the U.S.
Food and Drug Administration’s Guidance on Industry-Supported Scientific and
Educational Activities ("Policy Statement").
The Policy Statement and the ACCME Standards require, among other things, that
(i) Institution conduct the Program independently and without control or influence by
AstraZeneca over the Program's planning, content (including the selection of
speakers or moderators), or execution; (ii) the Program be free of commercial bias
for or against any product; (iii) Institution make meaningful disclosure of AstraZeneca
support of the Program and any prior relationship between Institution and
AstraZeneca, and the relationship, if any, between AstraZeneca and the speakers
selected by Institution; and (iv) AstraZeneca not engage in, and Institution not permit
any other sponsor to engage in, promotional activities in or near the Program room
or advertise its products in any materials disseminated as part of the Program.
In addition, Institution is required by the Policy Statement and the ACCME Standards
to ensure that any product discussions at the Program be accurate, objective,
balanced and scientifically rigorous. This includes a balanced discussion of each
product and of treatment alternatives, that limitations on data be disclosed, that
unapproved uses be identified as such, and that for live presentations there be
opportunities for questioning or debate.
REMINDER - Submission Instructions:
Call for Grants Application Title: “CGA CV 1601– Program Title…”
Submission Instructions:
• Your title must begin with Call for Grants Application (CGA) ID number.
• Refer to Grant Submission Instructions for further information on
submitting your formal grant application.